TrialScientific reports2025

Mirabegron nighttime versus daytime dosing for women with overactive bladder syndrome: a randomized controlled trial.

Sheng-Mou HsiaoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.